SGLT-2 Inhibitors and Autoimmune Rheumatic Disease Risk Reduction in Type 2 Diabetes: Insights from a Korean Nationwide Cohort

Highlight

• A large retrospective cohort study from South Korea evaluates SGLT-2 inhibitors versus sulfonylureas on autoimmune rheumatic disease risk in adults with type 2 diabetes.
• SGLT-2 inhibitor initiation was associated with an 11% reduced risk of autoimmune rheumatic diseases over a median follow-up of nine months.
• The risk reduction was consistent across subgroups stratified by age, sex, baseline cardiovascular disease, obesity, and SGLT-2 inhibitor type.
• Positive and negative control outcomes (genital infections and herpes zoster) confirmed expected safety profiles and methodological robustness.

Study Background